Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) Gross Margin (2016 - 2026)

Champions Oncology has reported Gross Margin over the past 17 years, most recently at 83.9% for Q1 2026.

  • Quarterly results put Gross Margin at 83.9% for Q1 2026, down 550.0% from a year ago — trailing twelve months through Jan 2026 was 76.2% (down 3092.0% YoY), and the annual figure for FY2025 was 50.15%, down 3577.0%.
  • Gross Margin for Q1 2026 was 83.9% at Champions Oncology, down from 86.71% in the prior quarter.
  • Over the last five years, Gross Margin for CSBR hit a ceiling of 207.75% in Q2 2024 and a floor of 34.7% in Q1 2024.
  • Median Gross Margin over the past 5 years was 86.71% (2025), compared with a mean of 80.22%.
  • Biggest five-year swings in Gross Margin: skyrocketed 12189bps in 2024 and later tumbled -16660bps in 2025.
  • Champions Oncology's Gross Margin stood at 88.1% in 2022, then decreased by -4bps to 84.49% in 2023, then plummeted by -47bps to 44.93% in 2024, then skyrocketed by 93bps to 86.71% in 2025, then decreased by -3bps to 83.9% in 2026.
  • The last three reported values for Gross Margin were 83.9% (Q1 2026), 86.71% (Q4 2025), and 86.75% (Q3 2025) per Business Quant data.